Compare Snap Inc (SNAP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Snap Inc trades at $6.09 (market cap $9.83B), while State Street SPDR S&P Biotech ETF trades at $150.4 (market cap $10.11B). The key difference: Snap Inc and State Street SPDR S&P Biotech ETF are close in size by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Snap Inc for 68 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| SNAP | XBI | |
|---|---|---|
Market Cap | $9.83B | $10.11B |
Volume | 28,532,342 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $9.09 | $169.55 |
52-Week Low | $3.93 | $104.99 |
Typical Hold Time | 68 Days | 37 Days |
Enterprise Value | $11.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNAP trades at $5.81, up 0.17% on the day, with a bullish technical signal from moving averages. The company reported revenue of $5.93B in 2025, with a net loss narrowing to -$460M, improving its profit margin to -7.77%. Recent news highlights Snap's push into enterprise AR glasses with NVIDIA and Salesforce partnerships, driving investor optimism.
The outlook remains cautious as SNAP continues to post losses despite revenue growth. Analyst consensus is a 'Hold' with a $7.78 price target, suggesting modest upside. Key risks include intense competition, regulatory pressures, and the challenge of achieving profitability. The stock's valuation appears stretched with a high EV/EBITDA of 1,149.99.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
